급성 림프구성 백혈병 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 화학요법별, 용도별, 연령층별, 성별, 최종 용도별, 지역별, 부문 동향(2024-2030년)

Acute Lymphocytic Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Product, By Chemotherapy, By Application, By Age Group, By Gender, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 림프구성 백혈병 치료 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 급성 림프구성 백혈병 치료 시장 규모는 2030년까지 49억 9,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2024-2030년에 걸쳐 CAGR 7.0%를 나타낼 것으로 예측됩니다. 급성 림프구성 백혈병(ALL) 진단을 위한 공적/민간 이니셔티브 증가, 골수 생검수 증가, 기타 치료 옵션의 가용성은 ALL 치료의 채용을 증가시킬 것으로 예상되는 요인 입니다. 예를 들어, 유니세프(영국)의 The Baby Friendly Initiative Program과 캐나다 병원과 의료기관의 공동 접근 방식인 SickKids-Caribbean Initiative는 특정 자격 기준을 충족하는 ALL을 앓고 있는 유아에게 무료로 진단 치료 서비스를 제공하는 것을 목표로합니다.

또한 ALL 이환율 상승이 시장을 밀어올릴 것으로 예상됩니다. 이 질병은 5세 이하의 어린이 사이에서 유행합니다. ALL에 걸릴 위험은 0세에서 20세 사이에서 가장 높습니다. 반면 성인에게도 발병 위험이 있습니다. 이 질환으로 진단된 남성의 나이의 중앙값은 약 55세입니다.

급성 림프구성 백혈병 치료 시장 보고서 하이라이트

• 화학요법은 2023년 39.9%의 최대 시장 수익 점유율을 차지했습니다. 화학요법은 ALL 치료에서 높은 관해율과 장기 생존율을 달성하여 성공을 보여줍니다.
• 전구 B 세포 급성 림프구성 백혈병 부문은 2023년 40.4% 시장 점유율을 차지했습니다. 전구 B세포 급성 림프구성 백혈병(ALL)의 발병률은 진단기술의 향상에 의해 질병의 식별이 용이해진 등에 의해 최근 증가 경향에 있습니다.
• 소아(0-18세) 부문은 2023년에 63.9% 시장 점유율을 차지했습니다. 급성 림프구성 백혈병은 소아에서 가장 많이 보이는 암이며 소아암 전체의 약 25%를 차지합니다.
• 남성 부문은 2023년에 57.1% 시장 점유율을 차지했으며, 여성 부문은 예측 기간 동안 6.7%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예측됩니다.
• 북미의 급성 림프구성 백혈병 치료는 2023년 37.6%의 점유율로 지배적인 지위를 차지했습니다. 미국의 급성 림프구성 백혈병 치료는 2023년 89.3%의 점유율로 북미 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 급성 림프구성 백혈병 치료 시장의 변수, 동향, 범위

• 시장 소개/계통 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 급성 림프구성 백혈병 치료 시장 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 급성 림프구성 백혈병 치료 시장 : 제품별, 추정·동향 분석

• 부문 대시보드
• 급성 림프구성 백혈병 치료 시장 : 제품 변동 분석, 2023년과 2030년
• 화학요법
• 표적요법
• 방사선치료
• 줄기세포 이식

제5장 급성 림프구성 백혈병 치료 시장 : 용도별, 추정·동향 분석

• 부문 대시보드
• 급성 림프구성 백혈병 치료 시장 : 용도 변동 분석, 2023년과 2030년
• 필라델피아 염색체
• 전구 B세포 ALL
• T세포 ALL

제6장 급성 림프구성 백혈병 치료 시장 : 연령층별, 추정·동향 분석

• 부문 대시보드
• 급성 림프구성 백혈병 치료 시장 : 연령층 변동 분석, 2023년과 2030년
• 유아(0-18세)
• 성인(19세 이상)

제7장 급성 림프구성 백혈병 치료 시장 : 성별, 추정·동향 분석

• 부문 대시보드
• 급성 림프구성 백혈병 치료 시장 : 성별 변동 분석, 2023년과 2030년
• 남성
• 여성

제8장 급성 림프구성 백혈병 치료 시장 : 최종 용도별, 추정·동향 분석

• 부문 대시보드
• 급성 림프구성 백혈병 치료 시장 : 최종 용도 변동 분석, 2023년과 2030년
• 병원 및 클리닉
• 암 케어 센터
• 연구 및 학술기관

제9장 급성 림프구성 백혈병 치료 시장 :지역별, 추정·동향 분석

• 급성 림프구성 백혈병 치료 시장 점유율, 지역별, 2023년과 2030년, 100만 달러
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 프로파일
  • Bristol-Myer Squibb Company
  • Celegene Corporation
  • Eisai Co., Ltd.
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GSK plc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

JHS

영문 목차

영문목차

Acute Lymphocytic Leukemia Therapeutics Market Growth & Trends:

The global acute lymphocytic leukemia therapeutics market size is anticipated to reach USD 4.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.0% from 2024 to 2030. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Acute Lymphocytic Leukemia Therapeutics Market Report Highlights:

• Chemotherapy accounted for the largest market revenue share of 39.9% in 2023. Chemotherapy has shown success in the treatment of ALL by achieving high rates of remission and long-term survival.
• The precursor B-cell acute lymphocytic leukemia segment accounted for the market share of 40.4% in 2023. The incidence of precursor B-cell ALL has been increasing in recent years due to several factors such as improvements in diagnostic techniques, which have led to better identification of the disease.
• The children (0-18) segment accounted for the market share of 63.9% in 2023. Acute lymphocytic leukemia is the most common type of cancer in children, accounting for about 25% of all childhood cancers.
• The male segment accounted for the market share of 57.1% in 2023 and the female segment is expected to register a CAGR of 6.7% during the forecast period.
• North America acute lymphocytic leukemia therapeutics held a dominant position with a share of 37.6% in 2023. The U.S. acute lymphocytic leukemia therapeutics dominated the North America market with a share of 89.3% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Acute Lymphocytic Leukemia Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Acute Lymphocytic Leukemia Therapeutics Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Acute Lymphocytic Leukemia Therapeutics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Acute Lymphocytic Leukemia Therapeutics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Chemotherapy
  • 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.1. Hyper-CVAD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.2. CALGB 8811 Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.3. Linker Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.4. Nucleoside Metabolic Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.5. Oncaspar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Radiation Therapy
  • 4.5.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Stem Cell Transplantation
  • 4.6.1. Stem Cell Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acute Lymphocytic Leukemia Therapeutics Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Acute Lymphocytic Leukemia Therapeutics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Philadelphia Chromosome
  • 5.3.1. Philadelphia Chromosome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Precursor B-cell ALL
  • 5.4.1. Precursor B-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. T-cell ALL
  • 5.5.1. T-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Children (0-18)
  • 6.3.1. Children (0-18) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Adults (19 +)
  • 6.4.1. Adults (19 +) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acute Lymphocytic Leukemia Therapeutics Market: Gender Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Acute Lymphocytic Leukemia Therapeutics Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
• 7.3. Male
  • 7.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Female
  • 7.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acute Lymphocytic Leukemia Therapeutics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Acute Lymphocytic Leukemia Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
• 8.3. Hospitals & Clinics
  • 8.3.1. Hospitals & clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Cancer Care Centers
  • 8.4.1. Cancer Care Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Research and academic institutes
  • 8.5.1. Research and Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Acute Lymphocytic Leukemia Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Acute Lymphocytic Leukemia Therapeutics Market Share, By Region, 2023 & 2030, USD Million
• 9.2. North America
  • 9.2.1. North America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. U.S. Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Canada Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Mexico Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. UK Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Germany Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. France Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Italy Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Spain Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Denmark Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Sweden Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Norway Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. China
    • 9.4.2.1. China Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Japan
    • 9.4.3.1. Japan Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. India Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. South Korea
    • 9.4.5.1. South Korea Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Australia
    • 9.4.6.1. Australia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Thailand Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Brazil Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Argentina Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. South Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Saudi Arabia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. UAE Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Kuwait Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Heat Map Analysis
• 10.4. Company Profiles
  • 10.4.1. Bristol-Myer Squibb Company
    • 10.4.1.1. Participant's Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Recent Developments/ Strategic Initiatives
  • 10.4.2. Celegene Corporation
    • 10.4.2.1. Participant's Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Recent Developments/ Strategic Initiatives
  • 10.4.3. Eisai Co., Ltd.
    • 10.4.3.1. Participant's Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Recent Developments/ Strategic Initiatives
  • 10.4.4. Erytech Pharma
    • 10.4.4.1. Participant's Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Recent Developments/ Strategic Initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd
    • 10.4.5.1. Participant's Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Recent Developments/ Strategic Initiatives
  • 10.4.6. Genmab A/S
    • 10.4.6.1. Participant's Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Recent Developments/ Strategic Initiatives
  • 10.4.7. GSK plc.
    • 10.4.7.1. Participant's Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Recent Developments/ Strategic Initiatives
  • 10.4.8. Novartis AG
    • 10.4.8.1. Participant's Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Recent Developments/ Strategic Initiatives
  • 10.4.9. Pfizer Inc.
    • 10.4.9.1. Participant's Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Recent Developments/ Strategic Initiatives
  • 10.4.10. Sanofi
    • 10.4.10.1. Participant's Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Recent Developments/ Strategic Initiatives

관련자료